Yoshida, Masaki http://orcid.org/0000-0002-9057-2277
Gotoh, Momokazu
Yokoyama, Osamu
Kakizaki, Hidehiro
Yamanishi, Tomonori
Yamaguchi, Osamu
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy of TAC-302 for patients with detrusor underactivity and overactive bladder: a randomized, double-blind, placebo-controlled phase 2 study
https://doi.org/10.1007/s00345-022-04163-4
Funding for this research was provided by:
Taiho Pharmaceutical
Article History
Received: 5 April 2022
Accepted: 21 September 2022
First Online: 7 October 2022
Declarations
:
: M. Yoshida has received consultancy fees from Taiho Pharmaceutical Co., Ltd. and speaker fees from KYORIN Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Astellas Pharma Inc., Ferring Pharmaceuticals Co., Ltd., and Pfizer Inc. M. Gotoh has received consultancy fees from Taiho Pharmaceutical Co., Ltd., Lilium Otsuka Co., Ltd., and speaker fees from Astellas Pharma Inc., Kissei Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Ferring Pharmaceuticals Co., Ltd., and Glaxo Smith Kline Plc. O. Yokoyama has received consultancy fees from Taiho Pharmaceutical Co., Ltd., Glaxo Smith Kline Plc., and Astellas Pharma Inc. and speaker fees from Glaxo Smith Kline Plc., Astellas Pharma Inc., and Kissei Pharmaceutical Co., Ltd. H. Kakizaki has received consultancy fees from Taiho Pharmaceutical Co., Ltd., and Astellas Pharma Inc., and speaker fees from Astellas Pharma Inc., Kissei Pharmaceutical Co., Ltd., Pfizer Inc., KYORIN Pharmaceutical Co., Ltd., and Ferring Pharmaceuticals Co., Ltd. T. Yamanishi has received consultancy fees from Taiho Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Pfizer Inc., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Nippon Shinyaku Co., Ltd., Nihon Kohden Corp., and Coloplast Corp. O. Yamaguchi has received consultancy fees from Astellas Pharma Inc., Taiho Pharmaceutical Co., Ltd., and Ferring Pharmaceuticals Co., Ltd., and speaker fees from Astellas Pharma Inc.
: Only humans participated in this study. The study protocol was approved by an Institutional Review Board at each participating institution, and the study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki, the Pharmaceutical and Medical Device Act, and the ministerial ordinance on Good Clinical Practice.
: Informed consent was obtained from all participants.
: The policy on data sharing of the study sponsor, Taiho Pharmaceutical Co., Ltd. may be found at ExternalRef removed.